NU Skin Enterprises Inc

Análisis de la acción NU Skin Enterprises Inc (NUS)

$4.990

+0.308 (+6.17%)Al cierre

Loading chart…
Máximo
5.130
Apertura
4.830
Precio medio ponderado por volumen
4.98
Volumen
646.13K
Capitalización
536.41M
Mínimo
4.830
Importe
3.22M
EV/EBITDA, TTM
2.16

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others.

www.nuskin.com

Análisis de IA of NU Skin Enterprises Inc (NUS)

Comprar

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

Recomendaciones de analistas (6)

Comprar
3 Comprar
1 Mantener
2 Vender
Actual: 4.99
Mínimo
—
Promedio
—
Máximo
—

DA Davidson

2024-12-20

Precio objetivo

$7

Mantener

Citigroup

2024-10-22

Precio objetivo

$6.75

Mantener

DA Davidson

2024-08-12

Precio objetivo

$11

Mantener

Citigroup

2024-08-09

Precio objetivo

$12

Mantener

DA Davidson

2024-05-09

Precio objetivo

$13

Mantener

Métricas de valoración

El PER previsto actual de NU Skin Enterprises Inc (NUS) es 4.12, frente a su media de 5 años de 11.03.

PER previsto

Infravalorado
Media 5A P/E
11.03
P/E actual
4.12
Sobrevalorada
16.12
Infravalorada
5.93

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
5.36
EV/EBITDA actual
2.16
Sobrevalorada
8.39
Infravalorada
2.34

Precio/ventas previsto

Infravalorado
Media 5A P/S
0.51
P/S actual
0.16
Sobrevalorada
0.84
Infravalorada
0.18

Escenarios de precio de Alphio AI para NUS

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%NUS

$6.63

Precio del escenario

B

Base

Base · 50%NUS

$6.29

Precio del escenario

B

Bajista

Bajista · 25%NUS

$4.75

Precio del escenario

Ballenas con NUS en cartera

C

Castleknight Management LP

+ Con en carteraNUS

-5.48%

Rentabilidad a 3 meses

Cronología de eventos

2026-08-10 (ET)

16:30:00

Cuts FY26 Revenue View to $1.28B-$1.35B

16:30:00

Sees Q3 Revenue of $310M to $340M

2026-05-07 (ET)

16:10:00

Company Confirms FY26 Revenue Outlook of $1.35B to $1.5B

16:10:00

Nu Skin Q1 Revenue at $320.6M, Below Estimate

16:10:00

Sees Q2 Revenue of $330M-$360M

Noticias

Preguntas frecuentes sobre NUS, respondidas por Alphio AI

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of beauty and wellness solutions in approximately 50 markets worldwide. It has nine segments, consisting of its seven geographic Nu Skin segments - Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan - and two Rhyz segments - Manufacturing and Rhyz Other. Its beauty & skincare solutions include acne and blemishes, anti-aging, dark circles and puffiness, discoloration, dry skin, lines and wrinkles, and oily skin and pores. Its health & wellness solutions include gut health, bone and joint health, brain health, energy and stamina, heart health, immunity support, and protein and fitness. It offers various beauty devices, including ageLOC LumiSpa, Nu Skin RenuSpa iO and Prysm iO. Its ageLOC LumiSpa includes products such as LumiSpa iO Superpower Kit, ageLOC Rose Gold LumiSpa iO, LumiSpa Rose Gold Accent Twin Pack, and others. It operates in the Consumer Non-Cyclicals sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

NU Skin Enterprises Inc (NUS) is a good buy right now, trading at $4.78, which is significantly below its 52-week high of $11.67. The forward P/E ratio is 4.008, indicating potential undervaluation compared to future earnings. Additionally, the stock has shown a recent positive trend with a 5-day change of +1.92% and a 20-day change of +3.24%. However, a key risk is the net margin, which has dropped to -78.03% in Q2 2026, indicating potential ongoing profitability issues that investors should monitor closely.

6 analysts cover NUS: 3 rate it Buy, 1 Hold and 2 Sell.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar